RBI may go for 3 rate hikes from December quarter: report
RBI is expected to begin its rate hike cycle from December quarter, and may go for three rate hikes by 2019 taking the key policy rate to 6.75%, says a Morgan Stanley report
New Delhi: The Reserve Bank of India (RBI) is expected to begin its rate hike cycle from December quarter, and may go for three rate hikes by 2019 taking the key policy rate to 6.75%, says a Morgan Stanley Report.
According to the global financial services major, a significant overshoot of inflation relative to RBI’s target is not likely. Moreover, the economic recovery will be on a surer footing by the fourth quarter of 2018 and this might prompt the central bank to go for a rate hike.
“With end demand holding up well, private capex appears poised for a recovery later this year,” Morgan Stanley said in a research note. It further noted that, “as the economy enters into a full-fledged recovery, we expect the central bank to embark on a shallow rate hike cycle beginning October-December of 2018.”
The report said a recovery in private capex is likely later this year and this will boost economic growth. “We maintain our expectation for a recovery in real GDP growth to 7.5% in 2018 and further to 7.7% in 2019, from 6.4% in 2017,” the report said.
Over 2018-19, Morgan Stanley has pencilled in a total of only three rate hikes, taking the terminal policy rate to 6.75%. “We expect RBI to commence its rate hike cycle from the fourth quarter of 2018 , as we think that the MPC does have time to pause and assess more incoming data before acting in the December quarter,” the report noted.
In its first bi-monthly monetary policy for 2018-19, RBI left repo rate unchanged at 6%. The MPC maintained status quo for the fourth consecutive time since August last year.
- Write-offs at PSBs grow at faster clip than loan growth
- Monetary policy panel cites inflationary risks as reason for RBI rate hike
- Vivo invests ₹200 crore to ramp up manufacturing at Greater Noida facility
- Ad agency Rediffusion to launch new logo, vision
- CSIR lab develops potential clot buster drug for stroke, licences it for clinical trials